<DOC>
	<DOCNO>NCT02739386</DOCNO>
	<brief_summary>The research question address study follow : 1 . What prevalence ipilimumab use among adult history autoimmune disease receive treatment ipilimumab advance melanoma ? 2 . Do melanoma patient history autoimmune disease experience complication require hospitalization relate underlying autoimmune disease follow treatment ipilimumab ?</brief_summary>
	<brief_title>Study Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Received ipilimumab therapy 03/01/2011 6/30/2014 Aged 18 year old index date ( initiation ipilimumab ) Diagnosed melanoma index Documented history autoimmune disease Have least 6 month continuous pharmaceutical medical benefit enrollment prior index Have least 3 month continuous pharmaceutical medical benefit enrollment follow include index date Diagnosed melanoma NO record exposure ipilimumab No exposure nivolumab ( Opdivo Â® ) time</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>